CD274 and non-small cell lung carcinoma: In 2020, the FDA announced that Opdivo (nivolumab) plus Yervoy (ipilimumab) (given as intravenous injections) have therapeutic benefits for adult patients with unresectable malignant pleural mesothelioma (MPM), and NSCLC (with tumour PD-L1 expression ≥1% and no EGFR/ALK aberrations) as a first-line treatment [83].